Press Releases

TearClear Announces Positive Topline Results from CLEAR Phase 3 Study for the Treatment of Glaucoma with TC-002 (latanoprost ophthalmic solution 0.005%)

TearClear announces the successful initiation of its TC-002 Latanoprost Ophthalmic Solution Phase 3 trial

TearClear Files Investigational New Drug (IND) Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solution, 0.005%

TearClear Announces Successful Completion of Pre-IND Meeting with the FDA for a Preservative Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma

TearClear Appoints Robert Bailey to Board of Directors

TearClear Raises $22 Million to Advance Multiple Clinical Programs in Development

TearClear appoints Dr. Amir Shojaei Chief Development Officer

TearClear appoints Robert J. Dempsey Chief Executive Officer

TearClear Appoints Chief Scientific and Innovation Officer

TearClear Completes $4.5 Million Series A Financing and Introduces Leadership Team of Accomplished Ophthalmology Veterans